Oncology Nursing News Hosts Tweet Chat on Oncology Nursing Society's Annual Conference

Article

Oncology Nursing News® will be hosting its first tweet chat on May 23, at 1 p.m. ET, to discuss findings presented at the Oncology Nursing Society's Annual Conference, held May 17-20 in Washington, DC.

Oncology Nursing News® will be hosting its first tweet chat on May 23, at 1 p.m. ET, to discuss findings presented at the Oncology Nursing Society's (ONS) Annual Conference, held May 17-20 in Washington, DC.

“We are excited to launch the inaugural tweet chat on the oncology nursing society’s annual conference. This tweet chat will inform the audience on the highlights and news that came out of the conference,” said Michael J. Hennessy Jr., president of MJH Associates, parent company of Oncology Nursing News®.

Oncology Nursing News® welcomes all professionals within the oncology nursing specialty group to join the discussion using the hashtag #OncNurseConnect. Highlights to be discussed:

  • Clinical practice
  • Leadership management education
  • Advanced practice
  • Research
  • Professional development

Read more ONS Congress conference coverage

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
3 experts in this video
3 experts in this video
Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
Related Content
Graphic that resembles a stamp of approval reading "FDA Approved"

FDA Approves Perioperative Pembrolizumab in Head and Neck SCC

Bridget Hoyt
June 12th 2025
Article

The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.

The Vitals

What New Cancer Drugs Were Approved in 2023?

Lindsay Fischer
January 1st 2024
Podcast

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Photo of the FDA building

FDA Approves Mitomycin Intravesical Solution in Low-Grade NMIBC

Bridget Hoyt
June 12th 2025
Article

UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Graphic that resembles a stamp of approval reading "FDA Approved"

Taletrectinib Approved by FDA for ROS1+ Non-Small Cell Lung Cancer

Bridget Hoyt
June 11th 2025
Article

The tyrosine kinase inhibitor taletrectinib has been approved for use in patients with ROS1-positive non-small cell lung cancer.

Anatomical image of a person with a breast tumor

T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

Tim Cortese
June 11th 2025
Article

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.